|Bid||36.00 x 1200|
|Ask||36.05 x 4000|
|Day's Range||35.52 - 36.15|
|52 Week Range||27.88 - 40.97|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||14.27|
|Earnings Date||Oct 27, 2020|
|Forward Dividend & Yield||1.52 (4.25%)|
|Ex-Dividend Date||Nov 05, 2020|
|1y Target Est||41.79|
Both of these biotechs have promising COVID-19 programs. But one of them appears to have a clear edge.
The drive to quickly conquer Covid-19 has accelerated innovation across the health-care sector. Barron’s roundtable experts highlight the most promising developments and best investment bets.
COMPANY CLOSE UPDATES Terrence Horan Shares of Johnson & Johnson JNJ inched 0.68% higher to $145.66 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.